Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Progress defined - short-term efficacy, long-term effectiveness
Autore:
Kane, J;
Indirizzi:
Long Isl Jewish Med Ctr, Dept Psychiat, New York, NY USA Long Isl Jewish Med Ctr New York NY USA Dept Psychiat, New York, NY USA
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
, volume: 16, anno: 2001, supplemento:, 1
pagine: S1 - S8
SICI:
0268-1315(200101)16:<S1:PD-SEL>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-SCHIZOPHRENIC PATIENTS; PLACEBO-CONTROLLED TRIAL; BLIND OLANZAPINE TRIAL; NEGATIVE SYMPTOMS; DEPRESSIVE SYMPTOMS; ACUTE EXACERBATION; ANTIPSYCHOTIC OLANZAPINE; SCHIZOAFFECTIVE DISORDER; RESISTANT SCHIZOPHRENIA; HALOPERIDOL;
Keywords:
schizophrenia; antipsychotics; efficacy; symptomatology;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
61
Recensione:
Indirizzi per estratti:
Indirizzo: Kane, J Long Isl Jewish Med Ctr, Hillside Hosp, Dept Psychiat, 7559 263rd St, GlenOaks, NY 11004 USA Long Isl Jewish Med Ctr 7559 263rd St Glen Oaks NY USA 11004 4 USA
Citazione:
J. Kane, "Progress defined - short-term efficacy, long-term effectiveness", INT CLIN PS, 16, 2001, pp. S1-S8

Abstract

The management of schizophrenia continues to represent an enormous challenge, despite improvements in both drug therapy and family and community interventions. Treatment expectations have shifted from the primary goal of controlling positive symptoms to a more comprehensive approach, with the aim of providing relief in all symptom domains, preventing relapses, improving compliance and ultimately improving functional outcomes in patients with schizophrenia. The advent of a new generation of 'atypical' antipsychotics should aid clinicians in meeting these goals. These agents combine high antipsychotic efficacy with improved tolerability profiles, mainly through a low Liability for extrapyramidal symptoms. There is enough evidence from randomized, double-blind trials to demonstrate efficacy of atypical antipsychotics in improving global psychopathology, positive, negative, affective and cognitive symptoms, as well as preventing relapse during long-term use. Thesedrugs may, therefore, provide clinicians with a new and important additionfor first-line management of schizophrenia. (C) 2001 Lippincott Williams &Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/12/19 alle ore 12:32:41